CSF1R and malignant colon neoplasm: Validating these cellular and molecular insights, our experiments in a mouse model of colon cancer elucidated the tangible therapeutic benefits of a combined regimen of LNCs@CSF1R siRNA nanocarriers and anti-PD-1 antibodies.